Surgical exploration without resection in pancreatic and periampullary tumors: Report from a national database

Emil Sahlström, Johan Nilsson, Bobby Tingstedt, Magnus Bergenfeldt, Roland Andersson and Bodil Andersson

Abstract
Background and objective: Pancreatic and periampullary cancers are sometimes found to have a too advanced disease during surgery to allow resection. The aim was to describe characteristics, treatment, outcome, and time trends for patients that were planned for pancreatic surgery but found unresectable during surgery.
Methods: Data from the Swedish National Pancreatic and Periampullary Cancer Registry were used. All patients registered between January 2010 and August 2018 were included. The patient cohort was divided in two halves based on year of diagnosis.
Results: In total, 12,377 patients were included in the registry and finally 4568 patients were scheduled for surgery. During surgical exploration, 3879 (84.9%) patients underwent pancreatic resection, 658 (14.4%) patients were found unresectable, and 31 (0.7%) had no pancreatic resection due to other reasons (e.g. benign lesion, comorbidity). More patients underwent surgical exploration and resection during the second time period, but exploration without resection was unchanged (15.7% vs 13.7%; p = 0.062). Survival rates were lower among the unresectable patients with pancreatic and periampullary tumors compared to the resectable patients, including 30-day mortality (n = 17 (3.5%) vs n = 39 (1.6%), p = 0.004) and 90-day mortality (n = 72 (15.0%) vs n = 70 (2.8%), p < 0.001). Palliative surgery became less common during the second half of the time period (p < 0.001).
Conclusions: Unresectability is associated with an unfavorable prognosis. The frequency did not decrease during the study period, but palliative surgical procedures became less common.

Keywords
Pancreatic cancer, periampullary cancer, pancreatic resection, palliative surgery, unresectability, survival

Date received: 17 November 2019; accepted: 18 February 2020

Introduction
Surgery is the only curative option for patients with pancreatic and periampullary cancer since the majority of the tumors will progress despite chemotherapy and radiotherapy. Unfortunately, many of these tumors are found unresectable at the time of diagnosis since symptoms occur late in the progression of the disease. Only approximately 20%–25% of all patients diagnosed with pancreatic cancer are resectable. The surgical resection is however extensive and associated with complications, why patient selection must be done carefully.
The predicted resectability of a tumor in pancreas or the periampullary region is primarily based on the results of a computed tomography (CT)\(^4\). Unfortunately, the diagnostic accuracy of CT is low, and tumor spread is often underestimated. This is problematic since unnecessary laparotomy results in morbidity for the patient and increased costs. It also delays the start of palliative treatment. Around 10%–25% of all patients with pancreatic cancer undergoing potentially curative surgery are found to have an unresectable lesion during the operation\(^4\).

When a presumed resectable tumor turns out to be locally advanced or metastasized perioperatively, the option is to do nothing further or to perform endoscopy or palliative surgery, for example, hepaticojejunostomy and/or gastrojejunostomy (double bypass). The double bypass has earlier been considered somewhat of a standard treatment. However, recent studies have questioned the use of additional surgery in a palliative situation, suggesting a more conservative approach. This conclusion was motivated by the fact that perioperative palliative surgery did not prevent future complications. Patients who underwent a double bypass also experienced more severe complications, had longer hospital stay, and the start of palliative chemotherapy was delayed\(^5,6\).

The primary aim of this register study, using data from the Swedish National Pancreatic and Periampullary Cancer Registry, was to describe characteristics and outcome of all patients subjected to pancreatic surgery, with focus on patients that were found unresectable during surgical exploration, and to investigate if the surgery and resection rates have changed over time. The secondary aim was to evaluate the use and result of palliative surgery.

## Material and Methods

### Patients and Data Collection

The study was based on data from the Swedish National Pancreatic and Periampullary Cancer Registry, which is a multicenter, nationwide, non-selected cohort. The registry consists of six forms and contains both preoperative, perioperative, and postoperative information about the patients. A complete list of variables is available on the web page of the register\(^7\). National and regional data are analyzed, and the results are e-published once a year\(^8\).

All Swedish patients with a suspected malignant pancreatic lesion and all patients subjected to pancreatic surgery are included in the registry. The registry was established in 2010, and its validity and coverage has shown good results\(^9\). Register data were received up to 28 August 2018.

All patients registered between January 2010 until August 2018 were included. The patients were included regardless of the result of the histopathology. An unresectable tumor was defined as a locally advanced primary tumor, not possible to resect, or a metastasized disease. The tumor was considered locally advanced in the presence of non-resectable extensive venous tumor invasion (i.e. extensive invasion of the portal vein or the superior mesenteric vein) and/or non-resectable arterial tumor invasion (i.e. invasion of the superior mesenteric artery, the celiac axis, or the hepatic artery)\(^6,10\). Palliative surgery performed instead of radical surgery during the planned operation was recorded and analyzed.

For the survival analysis, only patients with histologically proven pancreatic and periampullary cancer were included (excluding endocrine tumors, benign lesions, chronic pancreatitis, metastasis from other cancers, unknown histopathology, see Table 1). Also, patients that underwent other resections (e.g. endoscopic polypectomy) and patients in a poor condition during surgery disabling resection (e.g. portal hypertension) were excluded.

The patients were divided in two based on whether he or she was diagnosed before or after 31 December 2013.

### Statistics

Data are presented as means with standard deviations (SDs) and medians with interquartile range (IQR). Baseline characteristics between patients with resectable and unresectable disease were compared using the Student’s t-test or the unpaired Mann–Whitney U test for continuous variables, and chi-square-test for categorical variables. The Kaplan–Meier estimate of the survivor function was used to estimate long-term survival. The log-rank test was used to compare survival difference between the groups.

All statistical analyses were made two-sided. A p-value <0.05 was considered significant. Statistical analysis and graphs were performed using Stata MP statistical package version 15.1, 2017 (StataCorp LP, College Station, TX, United States). Ethics were approved by the Regional Human Ethics Committee at Lund University (Dnr 2018/499).

### Results

In total, 12,377 patients were included in the Swedish National Pancreatic and Periampullary Cancer Registry. Gender distribution was even, 6292 patients (50.8%) were male and 6085 patients (49.2%) were female. Overall mean age at diagnosis was 69.4 ± 11.1 years, and the male patients were younger (68.9 ± 10.6 vs 69.9 ± 11.5 years, p < 0.001). At the time of diagnosis, 7061 patients (57.4%) were considered palliative and 5233 patients (42.6%) were planned for curative treatment (i.e. resection). Finally, 4568 of these patients (87.3%) underwent surgery. The number one reason for not performing surgery (n = 665) in the group planned for intervention was tumor progression, followed by will of the patient and comorbidity (Fig. 1). Neoadjuvant chemotherapy was administered to 190 patients (4.2%) who later underwent surgical exploration, with resection in 140 (73.7%) patients. More patients underwent exploration (with or without resection) during the
During surgery, 3879 patients (84.9%) were considered resectable, 658 patients (14.4%) were not resected due to a locally advanced or metastasized tumor situation, and 31 patients (0.7%) had no pancreatic resection due to benign disease, other malignant disease, other resection, or intraoperative too poor medical condition to allow resection (Fig. 1). More patients underwent resection during the second time period, but as for exploration no increase could be seen in the proportion when comparing with all patients (n = 1484 vs n = 2395, p = 0.062). When a tumor was deemed unresectable, the underlying cause was more often a metastasized disease than a locally advanced tumor (312 vs 169). In several cases, both a metastasized and locally advanced disease were found (Fig. 1).

The final result of the histopathology of the patients undergoing surgery, based on if the tumor was resected or not, is presented in Table 1. In the group that underwent pancreatic surgery, 15.5% (n = 600) were found to have a benign tumor, and in the unresectable group, 0.9% (n = 6) had a benign tumor.

Preoperative variables, in relation to if the disease was resected or not, are presented in Table 2. Several factors are as expected more common in unresectable patients, for example, involuntary weight loss, older age, higher C-reactive protein (CRP), and cancer antigen (CA) 19-9.

Over the last 9 years, 335 patients with an unresectable pancreatic cancer have received palliative surgery and 26 patients have undergone endoscopic palliative surgery during the surgical exploration. In 2015, the patient group who received conservative treatment was larger than the group

| Variable name | n | Unresectable tumor (n = 658) | Resectable tumor (n = 3879) |
|---------------|---|-----------------------------|-----------------------------|
| Pancreatic cancer | 2133 | 423 (64.3%) | 1710 (44.1%) |
| Distal cholangiocarcinoma | 273 | 26 (4.0%) | 247 (6.4%) |
| Duodenal cancer | 238 | 19 (2.9%) | 219 (5.6%) |
| Ampullary cancer | 300 | 13 (2.0%) | 287 (7.4%) |
| Endocrine cancer | 170 | 5 (0.8%) | 165 (4.3%) |
| Metastasis from other cancer | 75 | 19 (2.9%) | 56 (1.4%) |
| Benign lesion | 605 | 5 (0.8%) | 600 (15.5%) |
| Chronic pancreatitis | 153 | 9 (1.4%) | 144 (3.7%) |
| Other/unknown lesion | 590 | 139 (21.1%) | 451 (11.6%) |

Data are presented as absolute numbers (percentage).
who underwent palliative surgery. This was the first year since the establishment of the registry as palliative surgery was performed in less than half of the patients with an unresectable tumor (Fig. 2). The same decline in palliative surgery could be seen when comparing patients who were diagnosed in 2010–2013 and 2014–August 2018 (n = 167 (58.4%) vs n = 168 (41.8%), p < 0.001).

The palliative surgical procedure performed has changed over the last years (p = 0.001, Table 3). In the first time period, double bypass was performed on 86 patients (52.1% of the patients undergoing palliative surgery). In the second time period, the same procedure was done on 55 patients (30.7%). At the same time, an increase in intraoperative endoscopic procedures could be observed, the use on stents increased from 8 patients (4.8%) in the earlier time period, compared to 21 patients (11.7%) in the later.

In August 2018, 3178 patients (25.7%) were alive and 9199 patients (74.3%) were deceased. For the pancreatic and periampullary tumor group (2463 resected, 481 unresectable), 56 patients (1.9%) died within 30 days of surgery and 142 patients (4.8%) within 90 days of surgery. The 30-day mortality was higher among the unresectable patients compared to the resectable (n = 17 (3.5%) vs n = 39 (1.6%), p = 0.004). The same result was seen when analyzing 90-day mortality (n = 72 (15.0%) vs n = 70 (2.8%), p < 0.001). The survival rate was lower among the patients with an unresectable tumor compared to patients with a resectable tumor (p < 0.001) (Fig. 3).

### Discussion

In this study, we have investigated a national cohort of patients subjected to pancreatic surgery, including all diagnosis, and primarily focusing on the ones found unresectable during surgical exploration, with in-depth analysis of patients with pancreatic and periampullary tumors. Of the 4568 patients undergoing surgery, an unresectable tumor or a tumor spread was found in 658 cases. As expected, the survival rate was lower among the patients with an unresectable tumor compared to patients with a resectable tumor (p < 0.001) (Fig. 3).

### Table 2. Preoperative characteristics of the patient group with an unresectable tumor in comparison to the patient group with a resectable tumor.

| Variable name                  | n  | Unresectable tumor (n = 658) | Resectable tumor (n = 3879) | p-value |
|-------------------------------|----|-----------------------------|----------------------------|---------|
| Male gender                   | 4537| 345 (52.4%)                 | 2013 (51.9%)               | 0.799   |
| Presence of involuntary weight loss | 4435| 433 (65.8%)                 | 1624 (41.9%)               | <0.001  |
| Diabetes mellitus             | 4463| 187 (28.4%)                 | 749 (19.3%)                | <0.001  |
| Smoking                       | 4347| 106 (16.1%)                 | 597 (15.4%)                | 0.672   |
| Preoperative biliary drainage | 4459| 402 (61.1%)                 | 1701 (43.9%)               | <0.001  |
| ASA-score ≥3                  | 4469| 171 (26.0%)                 | 947 (24.4%)                | 0.356   |
| Age at diagnosis (years)*     | 4537| 67.8 (± 9.1)                | 65.4 (± 11.4)              | <0.001  |
| Diagnosis to surgery (days)** | 4485| 48 (34–69)                  | 54 (36–88)                 | <0.001  |
| Body mass index (kg/m²)*      | 4318| 24.7 (± 4.3)                | 25.6 (± 4.6)               | <0.001  |
| Hemoglobin (g/L)*             | 4338| 125.8 (± 16.2)              | 130.9 (± 15.6)             | <0.001  |
| Bilirubin (μmol/L)**          | 4272| 14 (7–30)                   | 11 (6–23)                  | <0.001  |
| C-reactive protein (mg/L)**   | 3962| 8 (3–22)                    | 4 (2–10)                   | <0.001  |
| CA 19-9 (kE/L)**              | 3078| 250 (39–1172)               | 34 (10–172)                | <0.001  |
| CEA (μmol/L)**                | 1234| 4 (2–8)                     | 3 (1–4)                    | <0.001  |
| WBC count (× 10⁹/L)**         | 4143| 7.7 (6.2–9.6)               | 7.2 (6.0–8.9)              | <0.001  |
| CA 19-9-bilirubin-ratio**     | 3022| 12.6 (2.3–74.3)             | 2.5 (0.9–10.2)             | <0.001  |

ASA: American Society of Anesthesiologists; CA: cancer antigen; CEA: carcinoembryonic antigen; WBC: white blood cells. Data are presented as absolute numbers (percentage) except where *mean (standard deviation) and **median (interquartile range).
patient material (1.9%). The higher mortality rates among the unresectable group in comparison to the resectable group were expected. A high 30-day mortality was also seen in a cohort including only pancreatic cancer patients\textsuperscript{12}. Having an unresectable tumor indicates a more disseminated disease, which should impact the expected survival negatively. As many as 15.1% of the patients with a non-resectable tumor died within 90 days in the present material including patients with pancreatic and periampullary cancer.

More patients underwent exploration and resection in the second time period, which is in line with previous findings\textsuperscript{13,14}. Some possible reasons is that the criteria for local resectability have been widen and neoadjuvant treatment has been introduced, enabling more patients to be treated with curative intent despite extensive vascular involvement\textsuperscript{15}. Also, the knowledge of premalignant lesions such as intraductal papillary mucinous neoplasm (IPMN) has been increasing, which could cause a rise in the amount of resections\textsuperscript{16,17}. The reason that the proportion compared to all patients in this register was unchanged is deemed due to a progressively increased inclusion of patients, where it initially was better coverage for those who were intended for resection compared to those who were palliative already at the time of the diagnosis\textsuperscript{19}.

Among patients who underwent surgical exploration, the proportion of patients with tumor resection did not increase. In an article including only pancreatic cancer patients, an increased resection rate was seen comparing 2009 and 2013, but still almost one-third of patients with surgical exploration for pancreatic cancer did not undergo resection\textsuperscript{12}. During the last years, a centralization of pancreatic surgery has been completed in many countries and the sensitivity of preoperative imaging has been improving\textsuperscript{9,12,19}. However, still exploration without resection is an important topic and problem, both for the individual patient that is subjected to unnecessary surgery with subsequent delay of palliative therapy and from a health economic perspective.

This study has highlighted a number of possible risk factors for having an unresectable pancreatic lesion. Many of these factors are known risk factors for unresectable pancreatic cancer, such as older age\textsuperscript{20}, involuntary weight loss\textsuperscript{21}, diabetes mellitus\textsuperscript{22}, lower hemoglobin\textsuperscript{23}, higher CRP\textsuperscript{24}, and higher CA 19-9\textsuperscript{25}. However, all registered patients did not have pancreatic or periampullary cancer. Some patients had premalignant tumors (e.g. IPMN), and some had metastases from other cancerous diseases. A smaller proportion even had benign lesions. Due to the heterogeneity in the patient material, it is not possible to make further or deeper analyzes of potential risk factors for unresectable disease. However, since surgical exploration without resection is common, with no decrease over time, a preoperative risk score may be important to improve the preoperative decision. This could be of value both for the individual patient as well as for resource allocation.

The study findings regarding the declining use of perioperative palliative surgery were expected. The results are in line with previous studies, which suggests a careful approach when a pancreatic tumor is deemed unresectable\textsuperscript{5,6}. The findings illustrate a paradigm shift regarding perioperative palliative surgery. Patients, who previously were subjected to double-bypass surgery, are now treated more conservatively. This results in less complications, and a shorter hospital stay for the patient\textsuperscript{6}.

While palliative surgery has decreased over time, the proportion of intraoperative endoscopic procedures, primarily

---

Table 3. Difference in choice of perioperative palliative intervention in 2010–2013 compared to 2014–2018.

| Type of perioperative palliative surgery performed | n 2010–2013 (n = 165) | n 2014–2018 (n = 179) |
|---------------------------------------------------|----------------------|----------------------|
| Hepaticojejunostomy                              | 67 29 (17.6%)        | 38 21.2%             |
| Gastroenteroanastomosis                          | 65 28 (17.0%)        | 37 20.7%             |
| Hepaticojejunostomy + gastroenteroanastomosis    | 141 86 (52.1%)       | 55 30.7%             |
| Wallstent                                         | 25 6 (3.6%)          | 19 10.6%             |
| Wallstent + gastroenteroanastomosis              | 4 2 (1.2%)           | 2 (1.1%)             |
| Other/unknown intervention                       | 42 14 (8.5%)         | 28 (15.6%)           |

Data are presented as absolute numbers (percentage). The difference between the performed palliative surgery and the two time eras is statistically significant (chi-square-test, p = 0.001).
with self-expanding metallic stents, has increased. These interventions are, unlike palliative surgery, usually performed only in case of a symptomatic biliary and/or gastric outlet obstruction, and can safely be performed both during surgery or postoperatively.26 Endoscopic procedures are favorable for several reasons. They do not affect morbidity as much as palliative surgery does, and the length of the hospital stay is shorter. The costs are also lower.27,28

The strengths of this study is the large patient material, that the registry is validated for registered data, and that the accuracy and coverage is reported annually. The study has limitations inherent to analysis of registry, for example, the availability of specific data, the quality of the source data, and the number of missing data.

In conclusion, surgical exploration without resection is common in patients scheduled for pancreatic surgery. An unresectable pancreatic or periampullary tumor is associated with an adverse prognosis, including also a high risk for early mortality. The rate of completed resections did not increase, but the use of perioperative palliative surgery decreased during the study period. For the future, more studies have to be done to improve the preoperative decision regarding if the patient is resectable or not.

Acknowledgements

The authors would like to thank all Swedish pancreatic surgeons for providing information and maintaining a high coverage of the data in the Swedish National Pancreatic and Periampullary Cancer Registry.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Ethics were approved by the Regional Human Ethics Committee at Lund University (Dnr 2018/499).

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research work was supported by grants from The Swedish Cancer Society, government grant for clinical research (http://www.skane.se/fou/alf) and Erik and Angelica Sparres research foundation.

ORCID iDs

Roland Andersson https://orcid.org/0000-0003-0778-8630
Bodil Andersson https://orcid.org/0000-0001-5591-0659

References

1. Gurusamy KS, Kumar S, Davidson BR et al: Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev 2014;2:CD010244.
2. Stathis A, Moore MJ: Advanced pancreatic carcinoma: Current treatment and future challenges. Nat Rev Clin Oncol 2010;7(3):163–172.
3. Schmidt CM, Powell ES, Yianoutsos CT et al: Pancreaticoduodenectomy: A 20-year experience in 516 patients. Arch Surg 2004;139(7):718–725; discussion 725–727.
4. Allen VB, Gurusamy KS, Takwoingi Y et al: Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev 2013;11:CD009323.
5. Spanheimer PM, Cyr AR, Liao J et al: Complications and survival associated with operative procedures in patients with unresectable pancreatic head adenocarcinoma. J Surg Oncol 2014;109(7):697–701.
6. Williamsson C, Wennerblom J, Tingstedt B et al: A wait-and-see strategy with subsequent self-expanding metal stent on demand is superior to prophylactic bypass surgery for unresectable periampullary cancer. HPB (Oxford) 2016;18(1):107–112.
7. Carlén-Hallström L: Register Variables. Regionalt cancercentrum Sydöst; 2018. Available at: https://www.cancercentrum.se/samverkan/cancerdiagnoser/bukspottkortel/kvalitetsregister/dokument/, March 17, 2020
8. Carlén-Hallström L: Annual Report. Regionalt cancercentrum Sydöst; 2018. Available at: https://www.cancercentrum.se/samverkan/cancerdiagnoser/bukspottkortel/kvalitetsregister/, March 17, 2020
9. Tingstedt B, Andersson B, Jonsson C et al: First results from the Swedish National Pancreatic and Periampullary Cancer Registry. HPB (Oxford) 2019;21:34–42.
10. Regionalt cancercentrum Sydöst: Bukspottkörtelcancer—Nationellt vårdprogram. Regionalt cancercentrum Sydöst; 2012. Available at: https://www.cancercentrum.se/samverkan/cancerdiagnoser/bukspottkortel/vardprogram/, March 17, 2020
11. Sabesan A, Gough BL, Anderson C et al: High volume pancreaticoduodenectomy performed at an academic community cancer center. Am J Surg 2019;218(2):349–354.
12. van der Geest LGM, Lemmens VEP, de Hingh IHJT et al: Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. Br J Surg 2017;104(11):1568–1577.
13. van der Geest LG, Besselink MG, van Gestel YR et al: Pancreatic cancer surgery in elderly patients: Balancing between short-term harm and long-term benefit. Acta Oncol 2016;55(3):278–285.
14. Riall TS, Sheffield KM, Kuo YF et al: Resection benefits older adults with locoregional pancreatic cancer despite greater short-term morbidity and mortality. J Am Geriatr Soc 2011;59(4):647–654.
15. Kneuerz PJ, Cunningham SC, Cameron JL et al: Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: Trends and lessons learned from a large, single institution experience. J Gastrointest Surg 2011;15(11):1917–1927.
16. Schmidt CM, White PB, Waters JA et al: Intraductal papillary mucinous neoplasms: Predictors of malignant and invasive pathology. Ann Surg 2007;246(4):644–651; discussion 651–654.
17. Turriini O, Schmidt CM, Pitt HA et al: Side-branch intraductal papillary mucinous neoplasms of the pancreatic head/uncinate: Resection or enucleation? HPB (Oxford) 2011;13(2):126–131.
18. Regionalt cancercentrum Sydöst: Årsrapport 2017. Regionalt cancercentrum Sydöst; Juni 2018. Available at: https://www.cancercentrum.se/globalassets/cancerdiagnoser/bukspottkortel/kvalitetsregister/pankreascancersarapport2017.pdf, March 17, 2020
19. Lee ES, Lee JM: Imaging diagnosis of pancreatic cancer: A state-of-the-art review. World J Gastroenterol 2014;20(24):7864–7877.
20. Chiang KC, Yeh CN, Ueng SH et al: Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer. World J Surg Oncol 2012;10:77.
21. Yildirim BA, Ozdemir Y, Colakoglu T et al: Impact of presence and degree of pretreatment weight loss in locally-advanced pancreatic cancer patients treated with definitive concurrent chemoradiotherapy. Pancreatology 2016;16(4):599–604.
22. Fan KY, Dholakia AS, Wild AT et al: Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. J Natl Compr Canc Netw 2014;12(1):50–57.
23. Bjerregaard JK, Mortensen MB, Jensen HA et al: Prognostic factors for survival and resection in patients with initial non-resectable locally advanced pancreatic cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012;83(3):909–915.
24. La Torre M, Nigri G, Cavallini M et al: The Glasgow Prognostic Score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol 2012;19(9):2917–2923.
25. Santucci N, Facy O, Ortega-Deballon P et al: CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients. Pancreatology 2018;18(6):666–670.
26. Ciambella CC, Beard RE, Miner TJ: Current role of palliative interventions in advanced pancreatic cancer. World J Gastrointest Surg 2018;10(7):75–83.
27. Roy A, Kim M, Christein J et al: Stenting versus gastrojejunostomy for management of malignant gastric outlet obstruction: Comparison of clinical outcomes and costs. Surg Endosc 2012;26(11):3114–3119.
28. Artifon EL, Sakai P, Cunha JE et al: Surgery or endoscopy for palliation of biliary obstruction due to metastatic pancreatic cancer. Am J Gastroenterol 2006;101(9):2031–2037.